<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00985543</url>
  </required_header>
  <id_info>
    <org_study_id>NCHECR-ENCORE3</org_study_id>
    <nct_id>NCT00985543</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.</brief_title>
  <acronym>ENCORE3</acronym>
  <official_title>Pharmacokinetics of Plasma Lopinavir/Ritonavir Over a 12 Hour Dosing Interval Following Administration of 400/100, 200/150, and 200/50 mg Twice Daily to HIV-negative Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetics of plasma lopinavir/ritonavir
      over a 12-hour dosing interval, following administration to male and female HIV−negative
      healthy volunteers of:

        1. Lopinavir/ritonavir 400/100 mg twice daily

        2. Lopinavir/ritonavir 200/150 mg twice daily

        3. Lopinavir/ritonavir 200/50 mg twice daily
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data during the development of lopinavir/ritonavir showed that lower drug doses had similar
      efficacy to the standard dose of 400/100mg twice daily. Lower drug doses are also associated
      with limited toxicity and cost.

      The purpose of this study is to assess the pharmacokinetics of plasma lopinavir/ritonavir
      following administration to male and female HIV−negative volunteers of 400/100mg, 200/150mg
      and 200/50mg lopinavir/ritonavir twice daily. Each dosing phase will last for 7 days and each
      phase will be separated by a 7-day wash-out period. Pharmacokinetic evaluations will be made
      over a 12-hour interval at the end of each dosing phase.

      Healthy subjects as determined by their medical history and physical examinations will be
      eligible to participate in the study. HIV−positive subjects will not be recruited as there is
      a risk that HIV−resistant mutations will be selected by an experimentally reduced dose of
      lopinavir/ritonavir. There is no reason to presume that there is any meaningful difference in
      the metabolic processing of lopinavir/ritonavir between HIV−infected and HIV−uninfected
      people.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Lopinavir/Ritonavir Concentrations as Measured by the Area Under the Curve (AUC 0-12h).</measure>
    <time_frame>at the end of each 7-day dosing phase</time_frame>
    <description>Pharmacokinetics of plasma lopinavir/ritonavir over a 12-hour dosing interval following administration of lopinavir/ritonavir 400/100mg, 200/150mg and 200/50mg twice daily.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 11 weeks from screening to final study visit</time_frame>
    <description>Number of reported adverse events, severity of adverse events and relationship to study drug was assessed by questions, physical examination and laboratory parameters. Adverse event data was used to assess the safety and tolerability of low lopinavir/ritonavir doses.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <arm_group>
    <arm_group_label>LPV/r 400/100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lopinavir/ritonavir 400/100 mg twice daily (2 heat-stable 200/50 mg tablets twice daily (BID))</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LPV/r 200/150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lopinavir/ritonavir 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LPV/r 200/50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lopinavir/ritonavir 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lopinavir/ritonavir</intervention_name>
    <description>Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.</description>
    <arm_group_label>LPV/r 400/100 mg</arm_group_label>
    <arm_group_label>LPV/r 200/150 mg</arm_group_label>
    <arm_group_label>LPV/r 200/50 mg</arm_group_label>
    <other_name>Meltrex</other_name>
    <other_name>Ritonavir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must meet all of the following inclusion criteria within 28 days prior to the
             baseline visit:

               1. The ability to understand and sign a written informed consent form, prior to
                  participation in any screening procedures and must be willing to comply with all
                  study requirements

               2. Male or non-pregnant, non-lactating females

               3. Between 18 to 65 years, inclusive

               4. Body Mass Index (BMI) of 18 to 35 kg/m2, inclusive.

               5. Women of childbearing potential (WOCBP) must be using an adequate method of
                  contraception to avoid pregnancy throughout the study and for a period of at
                  least 1 month after the study

        Exclusion Criteria:

          1. Any significant acute or chronic medical illness

          2. Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, ECG or clinical laboratory determinations

          3. Positive blood screen for hepatitis B core and/or C antibodies and/or hepatitis B
             surface antigen

          4. Positive blood screen for HIV-1 and/or 2 antibodies

          5. Current or recent (within 3 months) gastrointestinal disease

          6. Clinically relevant alcohol or drug use (positive urine drug screen) or history of
             alcohol or drug use considered by the Investigator to be sufficient to hinder
             compliance with treatment, follow-up procedures or evaluation of adverse events.
             Smoking is permitted, but tobacco intake should remain consistent throughout the study

          7. Exposure to any investigational drug or placebo within 3 months of first dose of study
             drug

          8. Consumption of grapefruit, or Seville oranges or any grapefruit or Seville orange
             containing product within one week of first dose of study drug and for the duration of
             the study

          9. Use of any other drugs, including over-the-counter medications and herbal
             preparations, within two weeks prior to first dose of study drug, unless
             approved/prescribed by the Principal Investigator as known not to interact with study
             drugs.

         10. Females of childbearing potential without the use of effective non-hormonal birth
             control methods, or not willing to continue practising these birth control methods for
             at least 30 days after the end of the treatment period

         11. Previous allergy to any of the constituents of the pharmaceuticals administered in
             this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Boffito, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chelsea and Westminster Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Stephen's Centre, Chelsea and Westminster Hospital</name>
      <address>
        <city>London</city>
        <zip>SW10 9TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2009</study_first_submitted>
  <study_first_submitted_qc>September 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2009</study_first_posted>
  <results_first_submitted>February 4, 2011</results_first_submitted>
  <results_first_submitted_qc>March 2, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 29, 2011</results_first_posted>
  <last_update_submitted>March 2, 2011</last_update_submitted>
  <last_update_submitted_qc>March 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Marta Boffito</name_title>
    <organization>Chelsea and Westminster Hospital</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>ART</keyword>
  <keyword>HAART</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Lopinavir/ritonavir</keyword>
  <keyword>Lower dose selection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>All participants were given three sequential doses of lopinavir/ritonavir: lopinavir/ritonavir 400/100mg twice daily (2 heat-stable 200/50mg tablets BID), lopinavir/ritonavir 200/150mg twice daily (1 heat-stable 200/50mg tablet BID plus 1 ritonavir 100mg capsule BID), lopinavir/ritonavir 200/50mg twice daily (1 heat-stable 200/50mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period. Pharmacokinetic evaluations were made over a 12-hour interval at the end of each dosing phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All participants were given three sequential doses of lopinavir/ritonavir: lopinavir/ritonavir 400/100mg twice daily (2 heat-stable 200/50mg tablets BID), lopinavir/ritonavir 200/150mg twice daily (1 heat-stable 200/50mg tablet BID plus 1 ritonavir 100mg capsule BID), lopinavir/ritonavir 200/50mg twice daily (1 heat-stable 200/50mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period. Pharmacokinetic evaluations were made over a 12-hour interval at the end of each dosing phase.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Lopinavir/Ritonavir Concentrations as Measured by the Area Under the Curve (AUC 0-12h).</title>
        <description>Pharmacokinetics of plasma lopinavir/ritonavir over a 12-hour dosing interval following administration of lopinavir/ritonavir 400/100mg, 200/150mg and 200/50mg twice daily.</description>
        <time_frame>at the end of each 7-day dosing phase</time_frame>
        <population>22 participants completed the three sequential dosing phases and pharmacokinetic evaluations as per protocol. The same 22 participants are in the analysis population for each lopinavir/ritonavir dose (arm).</population>
        <group_list>
          <group group_id="O1">
            <title>LPV/r 400/100 mg</title>
            <description>Lopinavir/ritonavir 400/100 mg twice daily (2 heat-stable 200/50 mg tablets twice daily (BID))</description>
          </group>
          <group group_id="O2">
            <title>LPV/r 200/150 mg</title>
            <description>Lopinavir/ritonavir 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID)</description>
          </group>
          <group group_id="O3">
            <title>LPV/r 200/50 mg</title>
            <description>Lopinavir/ritonavir 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Lopinavir/Ritonavir Concentrations as Measured by the Area Under the Curve (AUC 0-12h).</title>
          <description>Pharmacokinetics of plasma lopinavir/ritonavir over a 12-hour dosing interval following administration of lopinavir/ritonavir 400/100mg, 200/150mg and 200/50mg twice daily.</description>
          <population>22 participants completed the three sequential dosing phases and pharmacokinetic evaluations as per protocol. The same 22 participants are in the analysis population for each lopinavir/ritonavir dose (arm).</population>
          <units>ng.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99599" lower_limit="87180" upper_limit="113787"/>
                    <measurement group_id="O2" value="73603" lower_limit="65121" upper_limit="83191"/>
                    <measurement group_id="O3" value="45146" lower_limit="39251" upper_limit="51927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dosing regimens lopinavir/ritonavir 200/150mg BID (Phase 2) and lopinavir/ritonavir 200/50mg BID (Phase 3) will be considered equivalent to lopinavir/ritonavir 400/100mg BID (Phase 1) if the 90% confidence interval (CI) for the mean AUC0–12h ratio and maximum concentration (Cmax) ratio lie between 0.80 and 1.25.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Results are considered statistically significant at p&lt;0.05 or when 90% confidence intervals do not cross the value 1. No adjustments are made for multiple comparisons.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>maximum likelihood regression</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Number of reported adverse events, severity of adverse events and relationship to study drug was assessed by questions, physical examination and laboratory parameters. Adverse event data was used to assess the safety and tolerability of low lopinavir/ritonavir doses.</description>
        <time_frame>Up to 11 weeks from screening to final study visit</time_frame>
        <population>22 participants completed the three sequential dosing phases and pharmacokinetic evaluations as per protocol. The same 22 participants are in the analysis population for each lopinavir/ritonavir dose (arm).</population>
        <group_list>
          <group group_id="O1">
            <title>LPV/r 400/100 mg</title>
            <description>Lopinavir/ritonavir 400/100 mg twice daily (2 heat-stable 200/50 mg tablets twice daily (BID))</description>
          </group>
          <group group_id="O2">
            <title>LPV/r 200/150 mg</title>
            <description>Lopinavir/ritonavir 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID)</description>
          </group>
          <group group_id="O3">
            <title>LPV/r 200/50 mg</title>
            <description>Lopinavir/ritonavir 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Number of reported adverse events, severity of adverse events and relationship to study drug was assessed by questions, physical examination and laboratory parameters. Adverse event data was used to assess the safety and tolerability of low lopinavir/ritonavir doses.</description>
          <population>22 participants completed the three sequential dosing phases and pharmacokinetic evaluations as per protocol. The same 22 participants are in the analysis population for each lopinavir/ritonavir dose (arm).</population>
          <units>number of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 11 weeks from screening visit until the participant's final study visit.</time_frame>
      <desc>Any adverse event that occurred after the reporting period that the PI assesses as possibly, probably or definitely related to the study drug was also reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Study Participants</title>
          <description>All participants were given three sequential doses of lopinavir/ritonavir: lopinavir/ritonavir 400/100mg twice daily (2 heat-stable 200/50mg tablets BID), lopinavir/ritonavir 200/150mg twice daily (1 heat-stable 200/50mg tablet BID plus 1 ritonavir 100mg capsule BID), lopinavir/ritonavir 200/50mg twice daily (1 heat-stable 200/50mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI shall not publish or otherwise disseminate the conclusions of the Study, including all or any part of the Results without the prior written consent of the Sponsor, such consent not to be unreasonably withheld or delayed. Any publication or other dissemination of the conclusions of the Study by the PI shall not occur until the Sponsor has published the conclusions of the Study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Marta Boffito</name_or_title>
      <organization>St Stephens Centre, Chelsea and Westminster Hospital</organization>
      <phone>+44 2088 466 507</phone>
      <email>marta.boffito@chelwest.nhs.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

